USD 21.3 Billion
Retinal Biologics Market Size, Share, Growth Analysis, By Indication(Macular Degeneration and Diabetic Retinopathy), By Drug Class(VEGF-A Antagonist and TNF-A Inhibitor), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35D2257 |
Region:
Global |
Published Date: May, 2024
Pages:
219
|Tables:
85
|Figures:
91
Retinal Biologics Market Insights
Global Retinal Biologics Market size was valued at USD 21.3 Billion in 2022 and is poised to grow from USD 22.9 Billion in 2023 to USD 41.17 Billion by 2031, at a CAGR of 7.61% during the forecast period (2024-2031).
The growing population is affected by retinal diseases such as age-related muscular degeneration, diabetic retinopathy and retinal vein occlusion. This surge can be attributed primarily to the aging population and advancements in biotechnology which have therefore increased the demand for more efficient treatments. Secondly, the retinal diseases were rising, notably AMT, which constitutes a substantial portion of cases. This research has emphasized the necessity for improved treatment options, therefore restoring research and development within the field. Thirdly, there has been advancement in biotechnology, genetic engineering and molecular biology, which have disclosed the path for the development of retinal biologic drugs. Some techniques such as gene therapy and cell-based therapy are showing further growth in the market. Furthermore, there has been growing awareness regarding retinal diseases, their diagnosis and available treatment which has played an important role. The organizations like Foundation Fighting Blindness and the American Macular Degeneration Foundation have played a main role in raising public awareness and supporting research attempts. Looking forward, there is a sub. Essential growth potential in emerging markets owing to improvement in healthcare infrastructure, the widespread existence of chronic diseases like diabetes, and increased awareness regarding early diagnosis and treatment options. The developing countries, such as China, Brazil and India also contributed to market growth as they have accepted VEGF-A antagonist treatments and make investments in healthcare infrastructure. Overall, the prospects for the retinal biologics market appear promising, which is driven by both developed and developing regions alike.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Hospital Pharmacy
Fastest Growth
Online Pharmacy
Growth Rate
7.61% CAGR
Global Retinal Biologics Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Retinal Biologics Market Segmental Analysis
The global retinal biologics market is segmented based on indication, drug class, distribution channel, and region. By indication, the market is segmented into Macular Degeneration and Diabetic Retinopathy. By drug class, the market is segmented into VEGF-A Antagonist and TNF-A Inhibitor. By distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Analysis By Indication
In the global retinal biologics market, the largest segment is macular degeneration as it is more common mostly in older people. It is prevalent in the elderly population, contributing to its dominant market share. Furthermore, there has been advancement in AMD treatment which has increased the use of retinal biologics in this segment.
On the other hand, the fastest-growing segment in the global retinal biologics market is diabetic retinopathy due to the increasing previous diabetes globally, particularly into eloping regions, which leads to a rise in diabetic retinopathy cases. Additionally, the new retinal biologic drugs have been introduced especially for diabetic retinopathy, along with a growing awareness and focus on early diagnosis and treatment. Is further increasing the growth of this segment.
Analysis By Drug Class
In the global retinal biologics market, the largest segment by backing material is VEGF-A Antagonist because it is widely used in retinal diseases such as age-related muscular degeneration, diabetic retinopathy and retinal vein occlusion. Drugs such as Ranibizumab and Aflibercept are mostly used as turn for these conditions, making the VEGF-A Antagonist dominant in the market.
On the other hand, the fastest-growing segment in the global retinal biologics market by drug class is TNF-A Inhibitor Because there is an increasing research and development focused on exploring the effectiveness of PFA inhibitors in treating retinal diseases, especially in cases where VEGF-A antagonists are not effective. Moreover, TNF-A inhibitors can provide alternative treatment options for patients who do not respond well to VEGF-A antagonist, contributing to this segment's rapid growth.
Analysis By Distribution Channel
In the global retinal biologics market, the largest segment is hospital pharmacy. Hospitals are the main centers for specialized eye care and treatment of retinal diseases, making them important for distributing retinal biology. Furthermore, hospitals own their infrastructure and staff to manage the storage, administration and monitoring of these complex biologic drugs, which are commonly provided through injection or infusion.
The fastest-growing segment in the global retinal biologics market is online pharmacy. This growth has surged by such as increasing Internet access, growing consumer preference for convenience and the availability of a wide range of retinal biologic drugs through online platforms. Furthermore, the COVID-19 pandemic has increased the adoption of online pharmacies, as patients seek alternative means to obtain their medicines while minimizing their exposure to healthcare facilities. This is expected to persist as online pharmacy offers increased availability and convenience for patients in need of retinal biologics.
Global Retinal Biologics Market By Distribution Channel
To get detailed analysis on other segments, Request For Free Sample Report
Retinal Biologics Market Regional Insights
The North America region has the highest revenue share in the global retinal biologics market. This is because more individuals are affected by retinal diseases, particularly among those with diabetes. This led to an increase in demand for treatments, which is a major driver of market expansion. In the United States, there are millions of people which are affected with diabetic retinopathy, which is a leading cause of vision impairment. This widespread occurrence creates a substantial market for treatment solutions. Additionally, some major companies are implementing strategic initiatives such as introducing new products, establishing partnerships and engaging in acquisitions. All these actions have contributed to the market's growth. For instance, Novartis obtained FDA approval for a novel treatment targeting diabetic macular edema, while Genentech's application for a treatment addressing various retinal diseases received FDA acceptance. If one combined these factors, North America emerges as a promising market for retinal biology with expectations of continued growth in the upcoming future.
On the other hand, Asia Pacific is the fastest growing region in the retinal biologics market. Some countries such as China, Japan and India, where awareness of retinal diseases and available treatment is quickly expanding, comes under this area. Furthermore, the enhancement of healthcare infrastructure and the increase in disposable incomes in various countries within the Asia Pacific region are also driving the demand for retinal biologics market.
Global Retinal Biologics Market By Region
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Retinal Biologics Market Dynamics
Drivers
Increasing Vision Problems
- In the United States, based on the information from centers for Disease Control and Prevention millions of individuals were diagnosed with diabetic retinopathy. Additionally, among these individuals some were identified with prone to developing retinopathy that could harm their vision. Diabetic retinopathy, which in turn is on the rise in America. The growing prevalence is anticipated to drive up the demand for treatments, mostly leading to increased market growth in the country.
Growing Cases of Diabetes
- Due to an increase in global diabetic population and projection of considerably increasing of the global diabetic population from 463 million in 2019 to an estimated 700 million by 2045 as per the International Diabetes Federation. Among these approximately 26.8% were reported to have experienced diabetic retinopathy and diabetic macular edema.
Restraints
High Cost Associated
- Retinal biologic drugs often come with high cost, which makes it difficult for the people in developing countries to access as it is difficult to afford by them. Also, the making and commercializing of these drugs is a complex process and involves strict regulatory requirements, which is estimated to further hinder market growth.
Request Free Customization of this report to help us to meet your business objectives.
Retinal Biologics Market Competitive Landscape
Several players such as Pharmaceuticals and Roche hold large market shares with well-established portfolios of retinal biologic drugs. These industry players basically lead research, development and commercialization efforts, which contributes to a consolidated market presence. On the same way, smaller biotechnology firms and startups play an important role in niche areas of retinal biologic research, representing fragmentation. This mix of established market leaders and emerging new companies encourages competition and drive innovation within the industry.
Top Player’s Company Profile
- Loxy Pfizer Inc.
- F Hoffmann La Roche Limited
- Merck and Co Inc.
- ABBVie Inc.
- Bayer AG
- Janssen Biotech
- Novartis AG
- Fresenius SE
- AstraZeneca, PLC
- Boehringer Ingelheim International GmbH
- Amgen Inc
- Teva pharmaceuticals industries limited
- Bristol-Myers Squibb
- Regeneron Pharmaceuticals, Inc
- Sun Pharmaceuticals Industries Limited
- Sanofi Genzyme
- Bausch & Lomb
- Santen Pharmaceuticak Co Ltd.
- Ocular Therapeutics
- Alimera Sciences
- Adverum Biotechnologies, Inc
- MeiraGTx Ltd.
- Oxurion NV
- Greybug Vision Inc.
- Kodiak Sciences Inc.
- Clearside Biomedical Inc.
- UCBCares
- Allergan plc
- Genentech Inc
- Iveric bio-Inc
- Neurotech Pharmaceuticals, Inc.
- Opthea Limited
Recent Developments
- In March 2024, Roche Pharma India, a part of the Swiss pharmaceutical company Roche, unveiled its highly anticipated medication called Vabysmo (faricimab) in India. This drug is pointed toward treating neovascular or "wet" age-related macular degeneration (nAMD) and diabetic macular edema (DME), which are two significant reasons for vision loss globally.
- In September 2023, the European Commission gave its approval for the first biosimilar of aflibercept. There will be an ongoing expansion of biosimilar offerings worldwide, which enhances their current portfolio in oncology and diabetes. This will positively impact patients in the EU who are dealing with muscular degeneration and diabetic retinopathy.
- In July 2023, Bausch & Lomb completed an acquisition of the Blink over the counter line (OTC) of eye drops from Johnson & Johnson Vision. This has widened company’s range of OTC eye care products thus allowing them to offer improves convenience to consumers.
Retinal Biologics Key Market Trends
- Genetic Treatment Approaches: There have been recent advances in gene therapy research for retinal diseases such as inherited retinal dystrophies are transforming the development and use of retinal biologic drugs.
- Therapies Targeting Vascular Endothelial Growth Factor: The VEGF remains a primary area for treating various eye diseases. There is ongoing research for the investigation and enhancement of these medications.
- Advancements in Retinal Imaging and Diagonostic Technologies: There have been recent developments in retinal imaging and diagnostic technologies which rate physicians in identifying retinal diseases with accuracy and at an earlier stage. This makes possible prompt initiation of treatment with biologic drugs.
Retinal Biologics Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global retinal biologics market analysis, the launch of new medications for retinal diseases and increasing market competition are estimated to drive market expansion. There have been more vision problems and diabetic retinopathy, which is projected to fuel the demand for retinal biologics in the upcoming future. Additionally, with vision issues, people are becoming more prevalent, so there is an expected rise in the necessity for retinal biologics market over time. Hospital pharmacy holds the highest share because they have access to many medications which are being prescribed by hospital staff and the online pharmacy is growing at a quick pace now a days. North America holds the highest share in the market as easy availability of drugs, health awareness, and treatment plays an important role for the growth of the market. Also, a well-developed infrastructure is available. Asia Pacific is growing quickly as it offers profitable market opportunity for players in this market. Gentetic treatment approaches has been a prominent trend in the retinal biologics market which has increased the use of retinal biologics drugs. The market is highly competitive and the key players in the market include pharmaceutical companies, research institutions and biotechnology firms.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 21.3 Billion |
| Market size value in 2031 | USD 41.17 Billion |
| Growth Rate | 7.61% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
Recent Developments
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Retinal Biologics Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Retinal Biologics Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Retinal Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Retinal Biologics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Retinal Biologics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Retinal Biologics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
